Trials Sponsors Conditions Drugs Pricing

Conditions

Facial Rejuvenation

Outcome Measures

Primary Outcomes (1)

Investigator Global Aesthetic Improvement Scale (GAIS) assessment at 12 weeks post-treatment
The blinded evaluator will assess subjects using the Global Aesthetic Improvement Scale (GAIS). The scale contains two questions: 1. Global aesthetic improvement - left side, and 2. Global aesthetic improvement - right side. Each question is rated on a 5-level scale: Level 1 = Very marked improvement, Level 2 = Marked improvement, Level 3 = Somewhat improved, Level 4 = No change, and Level 5 = Worse than before. The minimum value is 1 per item, and the maximum value is 5 per item. A lower score indicates a better outcome, meaning higher scores represent a worse outcome.
12 weeks (±7 days) post-treatment

Secondary Outcomes (13)

Global Aesthetic Improvement Scale (GAIS) assessment
1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment
Patient satisfaction with treatment
1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment
Improvement in skin elasticity and firmness
Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in transepidermal water loss
Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin hydration
Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment

Study Arms (2)

Left face A.G.E+Right face control

OTHER

The left side of the face serves as the experimental side, and the right side serves as the control side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream.

Other: Left face A.G.E+Right face control

Right face A.G.E+Left face control

OTHER

The left side of the face serves as the control side, and the right side serves as the experimental side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream.

Other: Right face A.G.E+Left face control

Interventions

Left face A.G.E+Right face controlOther

Left face A.G.E+Right face control

Right face A.G.E+Left face controlOther

Eligibility Criteria

Age30 Years - 60 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Female, aged 30-60 years;
Fine lines on both sides of the forehead meet Grade 1-5 according to the Skin Aging Atlas;

Sponsors & Collaborators

Beijing Artemis Medical Beauty Clinic
Otherlead

Study Sites (1)

Beijing Artemis Medical Beauty Clinic

Beijing, Beijing Municipality, China

RECRUITING

Xiaoge MaCONTACT+86 010-65666810 1621525631@qq.com

Lanping PuPRINCIPAL INVESTIGATOR

Central Study Contacts

Xiaoge Ma

CONTACT

+86 010-65666810 1621525631@qq.com

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: OUTCOMES ASSESSOR
Masking Details: To prevent the efficacy evaluator's knowledge of the group allocation from influencing their GAIS assessment, this clinical trial implemented blinding for the efficacy evaluator. The blinded evaluator is defined as a researcher who does not participate in the screening or intervention procedures of this study but conducts the efficacy evaluation. Their sole responsibility is to perform the GAIS assessment for subjects; they are not involved in any other aspects of this trial. The research documents completed by this evaluator are kept independent from those of the unblinded researchers, ensuring that the evaluator cannot obtain any information regarding the subjects' group allocation, thereby maintaining blinding of the group assignment. The blinded evaluator must not actively or passively acquire any information about the subjects' group allocation, and all other unblinded personnel must keep the blinding information confidential from the blinded evaluator. The blinded evaluator shal
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 22, 2026

First Posted

August 7, 2026

You may not qualify if:

Allergic constitution or history of severe allergies (e.g., immediate hypersensitivity symptoms, allergic dermatitis);
Presence of facial skin diseases (including severe freckles, atopic dermatitis, psoriasis, acute eczema, severe acne, etc.), skin infections (including viral, bacterial, fungal), or skin masses of unknown nature;
Presence of large areas of birthmarks, scratch marks, vitiligo, pigmented nevi, keloids, or other skin manifestations on the face that may affect the evaluation;
Presence of implantable electronic devices in the body (e.g., pacemaker, implantable cardioverter-defibrillator);
Diagnosed with serious clinical conditions such as endocrine diseases, immune system diseases, severe organ failure, or malignant tumors;
Diagnosed with severe mental illness or cognitive dysfunction, deemed by the investigator as unable to complete the evaluation or questionnaires involved in the study;
Received or planned to receive facial radiofrequency or botulinum toxin treatment within 6 months prior to enrollment or during the study;
Received chemotherapy or systemic corticosteroids within 3 months prior to enrollment;
Received or planned to receive facial photoelectric treatments (e.g., laser, intense pulsed light), fillers (e.g., sodium hyaluronate, collagen), thread lifts, or other aesthetic procedures within 3 months prior to enrollment or during the study;
Received or planned to receive facial mesotherapy or chemical peeling within 1 month prior to enrollment or during the study;
Used cosmetics, skincare products, or topical medications with firming or anti-wrinkle claims (e.g., glycolic acid, salicylic acid, mandelic acid, tretinoin, hydroquinone, azelaic acid, adapalene, etc.) on the face within 14 days prior to enrollment;
Other conditions that, in the investigator's judgment, render the subject unsuitable for unipolar radiofrequency treatment;
Pregnant or breastfeeding women;
Participated in other interventional clinical trials within 1 month prior to enrollment;
Other circumstances under which the investigator considers the subject should not participate in this clinical trial.

Unipolar Radiofrequency Treatment Combined With SkinCeuticals A.G.E. Ultra Cream for Facial Rejuvenation

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (13)

Study Arms (2)

Left face A.G.E+Right face control

Right face A.G.E+Left face control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (13)

Study Arms (2)

Left face A.G.E+Right face control

Right face A.G.E+Left face control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations